Latest in Cardiology from ACC.org

• DAPT-MVD: Extended DAPT Cuts CV Events After PCI in Multivessel CAD
  Extending DAPT for an additional year reduced major adverse cardiovascular events (MACE) without increasing bleeding risk compared with aspirin alone among patients with multivessel coronary artery disease (MVCAD) who had no ischemic or bleeding events one year after PCI with a drug-eluting stent, according to results of the DAPT-MVD trial published July 15 in NEJM.
• ACC Announces 2027 Officers and New Trustees
  The ACC Board of Trustees (BOT) has approved the College's next slate of officers and new trustees, who will begin their terms in April 2027 following ACC's Annual Scientific Session in Houston, TX.
• Does Influenza Vaccination Reduce AFib Risk?
  Influenza vaccination was associated with lower risks of incident atrial fibrillation (AFib) and multiple cardiovascular outcomes, according to an observational cohort study published July 11 in EHJ. The findings support vaccination as a potential AFib prevention strategy and underscore the need for randomized trials focused on AFib-related outcomes.
• GBD 2023: High SBP, Diet and High LDL-C Top Drivers of US IHD Deaths
  Nearly 90% of ischemic heart disease (IHD) deaths in 2023 in the U.S. were attributable to modifiable risk factors, led by high systolic blood pressure (SBP), dietary risks and high LDL-C, according to data from the Global Burden of Disease Study 2023 (GBD 2023), published July 15 in JAMA Cardiology.
• IL-6 as a Predictor of CV Risk Assessment: Role of Canakinumab and Ziltivekimab in Preventive Cardiology
  The 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia identified low-density lipoprotein cholesterol (LDL-C) as the primary lipoprotein for therapeutic targeting.1 Similarly, lipoprotein(a) [Lp(a)] and high-sensitivity C-reactive protein (hs-CRP) also have long-standing independent associations with the development of atherosclerotic cardiovascular disease (ASCVD).